Prevalence and Spectrum of BRCA1/2 Germline Mutations in Women with Breast Cancer in China Based on Next-Generation Sequencing

Background BRCA1 and BRCA2 (BRCA1/2) play important roles in the development of breast cancer, but information regarding BRCA1/2 mutations in Chinese females remains limited. The aim of this study was to investigate the prevalence and spectrum of BRCA1/2 mutations in China. Material/Methods In total, 595 breast cancer patients in China were screened with an amplicon-based panel for the detection of BRCA1/2 mutations in coding regions using next-generation sequencing (NGS) with a Personal Genome Machine. Every pathogenic mutation detected was confirmed by Sanger sequencing. The disease-causing potential of variants of uncertain significance (VUS) was predicted using PolyPhen-2, SIFT, PhyloP, and Grantham. Results The prevalence of BRCA1/2 mutations was 8.07% in the Chinese population. Forty-two pathogenic mutations were identified in 48 cases (17 BRCA1 cases and 31 BRCA2 cases), including 19 novel mutations. Nine VUS were predicted to be deleterious by PolyPhen-2 and SIFT and subsequently predicted by PhyloP and Grantham for the evolutionary conservation. Conclusions These results suggest that NGS is useful as a rapid, high-throughput, and cost-effective screening tool for the analysis of BRCA1/2 mutations. Based on this panel, we found that BRCA1/2 germline mutations in China exhibit distinct characteristics compared to those in Western populations.

• Publication year

  2018

• Venue

  Medical Science Monitor

• Publication date

  2018-04-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.12659/MSM.905812PMID 29681614PMCID 5936051
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genes

  2022cited by this paper
• BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic‐related mutations in BRCA1 associated with an increased risk of ovarian cancer

  2017cited by this paper
• The spectrum of BRCA mutations and characteristics of BRCA‐associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next‐generation sequencing

  2017cited by this paper
• Cancer statistics in China, 2015

  2016cited by this paper
• Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer

  2016cited by this paper
• Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis

  2016cited by this paper
• Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing

  2014cited by this paper
• The prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China

  2014cited by this paper
• Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis

  2012cited by this paper
• Development of a next-generation sequencing method for BRCA mutation screening: a comparison between a high-throughput and a benchtop platform.

  2012cited by this paper
• Meeting report: Current cancer perspectives from the 9th Annual Meeting of the Japanese Society of Medical Oncology

  2012cited by this paper
• Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes

  2012cited by this paper
• Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women

  2011cited by this paper
• Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer

  2011cited by this paper
• Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer

  2009cited by this paper
• "Westernizing" women's risks? Breast cancer in lower-income countries.

  2008cited by this paper
• The ubiquitin E3 ligase activity of BRCA1 and its biological functions

  2008cited by this paper
• The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified

  2008cited by this paper
• Prevalence of BRCA1 and BRCA2 mutations in Jewish women with triple negative breast cancer

  2008cited by this paper
• Network modeling links breast cancer susceptibility and centrosome dysfunction.

  2007cited by this paper
• Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.

  2006cited by this paper
• The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer

  2006cited by this paper
• Cellular functions of the BRCA tumour-suppressor proteins.

  2006cited by this paper
• Genetic Linkage Analysis in Familial Breast and Ovarian Cancer: Results from 214 Families

  2006cited by this paper
• Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients.

  2004cited by this paper
• Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

  2004cited by this paper
• The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives

  2003cited by this paper
• Founder mutation in the BRCA1 gene in Malay breast cancer patients from Singapore

  2003cited by this paper
• Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population.

  2002cited by this paper
• Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2

  2002cited by this paper
• Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families

  2001cited by this paper
• Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases

  2000cited by this paper
• BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history.

  1998cited by this paper
• Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.

  1997cited by this paper
• BRCA1 and BRCA2 Germline Mutations in Japanese with Hereditary Breast Cancer Families.

  1997cited by this paper
• Identification of the breast cancer susceptibility gene BRCA2

  1996cited by this paper
• The genetic attributable risk of breast and ovarian cancer

  1996cited by this paper
• Identification of the breast cancer susceptibility gene BRCA2

  1995cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

  1993cited by this paper

• Overview on population screening for carriers with germline BRCA mutation in China

  2022cites this paper
• Genetics and Genomics of Breast Cancer: update and translational perspectives.

  2020cites this paper
• Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high‐risk breast cancer

  2019influential citation
• Withaferin-A Inhibits Growth of Drug-Resistant Breast Carcinoma by Inducing Apoptosis and Autophagy, Endogenous Reactive Oxygen Species (ROS) Production, and Inhibition of Cell Migration and Nuclear Factor kappa B (Nf-κB)/Mammalian Target of Rapamycin (m-TOR) Signalling Pathway

  2019cites this paper